Recursion Pharmaceuticals Target of Unusually Large Options Trading (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) was the target of some unusual options trading activity on Friday. Stock investors purchased 62,593 call options on the company. This represents an increase of approximately 139% compared to the average volume of 26,225 call options.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on RXRX shares. KeyCorp reduced their price target on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Morgan Stanley cut their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating on the stock in a research note on Thursday, April 10th. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Leerink Partners cut their target price on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research report on Friday, February 28th. Finally, Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $8.20.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the stock. Decker Retirement Planning Inc. acquired a new position in Recursion Pharmaceuticals during the fourth quarter valued at approximately $26,000. Private Trust Co. NA acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth $27,000. GAMMA Investing LLC grew its position in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after purchasing an additional 4,948 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after purchasing an additional 1,353 shares during the period. Finally, NewEdge Advisors LLC increased its position in Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after buying an additional 2,387 shares during the period. Institutional investors and hedge funds own 89.06% of the company's stock.

Remove Ads

Recursion Pharmaceuticals Stock Up 0.5 %

RXRX traded up $0.03 on Tuesday, reaching $5.54. 14,014,959 shares of the company traded hands, compared to its average volume of 11,875,846. The stock's 50 day moving average price is $6.78 and its 200-day moving average price is $6.82. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. Recursion Pharmaceuticals has a 52-week low of $3.79 and a 52-week high of $12.36. The company has a market cap of $2.23 billion, a price-to-earnings ratio of -3.62 and a beta of 1.00.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last announced its quarterly earnings results on Friday, February 28th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.17). The firm had revenue of $4.60 million for the quarter, compared to analyst estimates of $19.04 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The firm's quarterly revenue was down 57.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.42) earnings per share. On average, sell-side analysts expect that Recursion Pharmaceuticals will post -1.57 EPS for the current fiscal year.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.